Immune checkpoint inhibitor (keytruda, opdivo, yervoy, tecentriq, imfinzi, libtayo) denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare covers immune checkpoint inhibitors (Keytruda/pembrolizumab, Opdivo/nivolumab, Yervoy/ipilimumab, Tecentriq/atezolizumab, Imfinzi/durvalumab, Libtayo/cemiplimab, and related agents) under the medical benefit when prescribed for cancer indications. This policy provides parameters for coverage of injectable oncology medications, including therapeutic radiopharmaceuticals, covered under the medical benefit based upon the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium, which lists appropriate drugs and biologics for specific cancers using US Food and Drug Administration (FDA)-approved disease indications and specific NCCN panel recommendations. UnitedHealthcare recognizes indications listed in the NCCN Drugs and Biologics Compendium with Categories of Evidence and Consensus of 1, 2A, and 2B as proven and medically necessary, and Category 3 as unproven and not medically necessary. Coverage is provided for the UnitedHealthcare preferred oncology product contingent on the diagnosis-specific criteria; coverage for any non-preferred product is contingent on both the Preferred Product Criteria and Diagnosis-Specific Criteria, and members new to therapy are required to use the preferred product unless they meet exception criteria. Preferred/non-preferred designations vary by indication—for example, in non-small cell lung cancer Keytruda Qlex is preferred; in head and neck cancers Keytruda Qlex is non-preferred; and in squamous cell skin cancer Libtayo is preferred while Keytruda, Keytruda Qlex, Opdivo, Opdivo Qvantig, and Unloxcyt are non-preferred. To qualify for a non-preferred product, the patient must have a history of intolerance or contraindication to a UnitedHealthcare preferred oncology product, and the physician must attest that the same intolerance, contraindication, or adverse event would not be expected with the non-preferred product. Keytruda is administered through the medical benefit but specialty pharmacy distribution is required: UnitedHealthcare classifies Keytruda as a specialty medication requiring prior authorization through OptumRx, typically placed on a high-cost specialty tier (Tier 5). Prior authorization is required, with reauthorization on a periodic basis, and specific PD-L1 expression thresholds (e.g., ≥50% for monotherapy first-line NSCLC) apply per the NCCN/FDA labels referenced in the policy.

- **Cite NCCN Category 1/2A recommendation for the exact indication**: UHC's own policy binds coverage to NCCN Compendium recommendations of Category 1, 2A, or 2B as proven and medically necessary . Quote the specific NCCN guideline page and category (e.g., NCCN NSCLC Guidelines list pembrolizumab + chemo as Category 1 for first-line metastatic non-squamous NSCLC; KEYNOTE-189 trial). - **Reference pivotal trial data supporting the FDA label**: For Keytruda in NSCLC cite KEYNOTE-024 (PD-L1 ≥50% monotherapy) and KEYNOTE-189/407 (combo with chemo); for Opdivo+Yervoy cite CheckMate-227/9LA; for Libtayo cite EMPOWER-Lung-1 and EMPOWER-CSCC-1; for Imfinzi cite PACIFIC (stage III NSCLC after chemoradiation); for Tecentriq cite IMpower150/133. - **Document preferred-product step therapy was met or is contraindicated**: Provide chart notes showing prior trial of the UHC preferred ICI with progression, intolerance, or a contraindication (e.g., active autoimmune disease, hypersensitivity), satisfying UHC's exception pathway as history of intolerance or contraindication to one of the UnitedHealthcare's preferred oncology products, and physician attests that the same intolerance, contraindication, or adverse event would not be expected to occur with the respective non-preferred product. - **Submit biomarker results**: Attach the PD-L1 IHC report (22C3/SP263), MSI/MMR or TMB testing report, and tumor histology confirming the FDA-labeled indication; for monotherapy NSCLC confirm PD-L1 expression positive ≥ 50% . - **Invoke ASCO and NCCN consensus**: ASCO Clinical Practice Guidelines (e.g., ASCO/ESMO guidelines for metastatic NSCLC, melanoma, RCC, HNSCC, urothelial carcinoma) concur with NCCN on ICI use; cite specific guideline year and recommendation grade. - **Cite UHC's medical-benefit step therapy carve-outs**: Continuation-of-therapy provisions apply when the member has been receiving the ICI; reference continuation of prior therapy within the past 365 days as grounds for approval without re-trying the preferred agent. - **Escalate to external/independent review with policy language**: Per practitioner experience, external reviews succeed when patients include a detailed timeline showing how UnitedHealthcare's denial contradicts their own published criteria, and independent medical reviewers appreciate clear, point-by-point rebuttals that reference the plan's policy language directly.

## Why UHC Step-Therapy Denials for Immune Checkpoint Inhibitors Are Frequently Overturned

UnitedHealthcare applies step-therapy (also called "fail-first") protocols to many oncology drugs, including immune checkpoint inhibitors such as pembrolizumab (Keytruda), nivolumab (Opdivo), ipilimumab (Yervoy), atezolizumab (Tecentriq), durvalumab (Imfinzi), and cemiplimab (Libtayo). A step-therapy denial means the plan is requiring evidence that you first tried and failed one or more alternative treatments before it will authorize the requested ICI. In oncology, these protocols carry special legal weight: most states have enacted step-therapy override laws requiring insurers to grant exceptions when a required step is clinically contraindicated, has already failed, or when the prescribed agent is a first-line standard of care for your specific cancer and biomarker profile.

## Why This Denial Is Appealable

For many cancers, these ICIs are recognized as first-line or preferred therapy in applicable oncology society guidelines (such as those issued by the relevant NCCN, ASCO, or ESMO committee). Requiring a patient to try an inferior or inappropriate prior therapy before accessing a guideline-recommended ICI can constitute a denial that is inconsistent with generally accepted standards of medical practice — a key legal standard under both ACA §2719 and ERISA §503. If your oncologist believes the required "step" drug is clinically inappropriate for your tumor type, biomarker status, or performance status, that clinical judgment — documented in writing — is the foundation of your appeal.

## Federal Appeal Framework

• Internal appeal: File under ERISA §503 or ACA §2719. Request the specific step-therapy criteria UHC applied and the clinical rationale for requiring the prior-step drug.
• State step-therapy override: If you are in a state with a step-therapy override statute, file a parallel override request citing clinical inappropriateness of the required step.
• External review: Escalate to an IRO within the approximately four-month window after final internal denial. IROs regularly reverse step-therapy denials where the prescribing oncologist documents first-line guideline support.
• Expedited review: Available given the serious and life-threatening nature of the underlying condition.

## Concrete Appeal Steps and Timeline

1. Obtain the insurer's step-therapy coverage policy in writing and identify exactly which prior-step drug(s) are required. 2. Have your oncologist document in writing why the required prior step is clinically inappropriate, contraindicated, or already effectively failed for your specific case. 3. Attach the applicable oncology society guideline recommendation (reference the organization and guideline name; do not need to recite specific numbers). 4. File the internal appeal and, if denied, escalate immediately to external review before the deadline on your denial notice.

## Documentation to Gather

• Diagnosis and biomarker documentation: Pathology, genomic/biomarker results, and tumor type establishing that the prescribed ICI is guideline-consistent first- or early-line therapy.
• Prior treatment history: Dates, regimens, and outcomes of any prior lines actually received, demonstrating what has already been tried.
• Clinical severity and urgency: Oncology notes on disease progression, performance status, and the clinical risk of delaying initiation.
• Prescriber letter on step-therapy override: Explicit statement that the required prior step is not appropriate for this patient's specific indication, biomarker profile, or clinical condition.

## Criteria-Mapping Structure

Pull the exact step-therapy requirements from UHC's published coverage policy. For each required step, create a row showing either (a) the date and outcome of that prior therapy in your chart, or (b) your oncologist's documented clinical reason why that step is not appropriate. A direct requirement-by-requirement response eliminates any ambiguity and gives the IRO a clear path to override the denial.